Preliminary Program

September 22, 2021

Session 1: Advances in Glycobiotechnology

Application of Biocatalysis in Glycobiotechnology
Sabine Flitsch, University of Manchester, UK

Warren Wakarchuk, University of Alberta, Canada

C-type lectin receptor targeting to modulate immune responses during infections
Bernd Lepenies, University of Veterinary Medicine Hannover, Foundation (TiHo), Research Center for Emerging Infections and Zoonoses (RIZ), Germany

Véronique Blanchard, Charité Universitätsmedizin Berlin, Germany

Erdmann Rapp, glyXera GmbH, Germany

Glycouniverse GmbH, Germany

Session 2: Potentials and Challenges of Digitalization in R&D and in Healthcare

Critically ill COVID-19 associated trait genetics reveals CDK6 inhibitors as potential treatment
Marco Schmidt, GmbH, Germany

Katja Uhlig, Fraunhofer Institute for Cell Therapy and immunology, Branch Bioanalytics and Bioprocesse (IZI-BB), Germany

Srujan Dondapathi, Fraunhofer Institute for Cell Therapy and immunology, Branch Bioanalytics and Bioprocesse (IZI-BB), Germany

September 23, 2021

Session 3: Trends in Antibody Technologies

Genetic Glycoengineering in Mammalian cells
Zhang Yang, University of Copenhagen and GlyoDisplay Aps, Denmark

Glycotope GmbH, Germany

Peter Sondermann, Tacalyx GmbH, Germany

Michael Hust, TU Braunschweig, Germany

Session 4: Emerging Concepts and Technologies in Vaccine Development

Targeted Delivery Systems for Antigen-Specific Immunotherapies
Robert Wawrzinek, Cutanos GmbH, Austria

RNA-based vaccines, technological challenge and opportunity for new therapies
Tilmann Roos, CureVac AG, Germany

Session 5: Innovations and Potentials through High-throughput Screenings

Jens Peter von Kries, FMP, Berlin, Germany

Niels Fertig, Nanion GmbH, Munich, Germany

September 24, 2021

Session 6: Translational Immunology in early life disease

in cooperation with the Monash University, Australia

Clinical proteomics: improving the outcomes for children
Vera Ignjatovic, University of Melbourne, Australia

New and emerging approaches to tackle the early life origins of disease
Dr Siroon Bekkering, Radboud Universitair Medisch Centrum, The Netherlands
David Burgner,  Murdoch Childrens Research Institute, Australia

Samuel Forster
Hudson Institute of Medical Research, Australia (Research Group Head, Microbiota and Systems Biology)

Philip DeKoninck
Monash University, Australia

Jose Polo
Monash University, Australia

Andrew Currie
Murdoch University, Australia

Session 7: Medicine and Health of Aging – Research, Therapy and Health Care

in cooperation with the Faculty of Health Sciences Brandenburg, Germany

Medicine and Health of Ageing – Current Research at the Faculty of Health Sciences Brandenburg
René Mantke, Faculty of Health Sciences Brandenburg, Brandenburg Medical School, Brandenburg an der Havel

Prevention and Therapy

„Lauflabor“ and „Antepulse“ – Innovative Approaches for Improving Vascular Health of Risk Patients
Ivo Buschmann, Brandenburg Medical School, Brandenburg an der Havel“

Healthcare Research and Digital Health

Mobile molecular diagnostics of viral diseases in human and veterinary medicine
Frank Hufert, Brandenburg Medical School, Senftenberg
Health by digitization and networked IT using distributed embedded systems
Michael Hübner, Brandenburg University of Technology Cottbus-Senftenberg

Age-Related Cell Alterations

Cell-based Immuno-Assays in In-Vitro-Diagnostics – from Tuberculosis to Covid-19
Werner Dammermann, Brandenburg Medical School, Brandenburg an der Havel

Molecular Mechanisms of cardiovascular Diseases
Stefanie Oess, Brandenburg Medical School, Brandenburg an der Havel

Program With Confirmed Speakers: Titles and Speakers are Subject to Change Without Notice